RSS   Newsletter   Contact   Advertise with us

Momenta Pharmaceuticals names new board member

Staff writer | Cambridge, Mass., USA | March 11, 2016
Jose Carlos Gutiérrez RamosMarch 11, 2016, Cambridge, Mass., USA - Momenta Pharmaceuticals, Inc., a biotechnology company, announced the appointment of Jose-Carlos Gutiérrez-Ramos to its board of directors.
Dr. Gutiérrez-Ramos currently serves as Chief Executive Officer and President of Synlogic Inc. and was previously Group Senior Vice President and Global Head of BioTherapeutics Research and Development at Pfizer. Dr. Gutiérrez-Ramos has served as Chief Executive Officer and President of Synlogic Inc., since May 2015.

Previously, he served as Group Senior Vice President and global head of the BioTherapeutics Research at Pfizer where he was responsible for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in Rare Disease Discovery and Development and founded the Centers for Therapeutic Innovation.

He also oversaw and enhanced the biologics platform for the company from early discovery to entry in manufacturing. Dr. Gutiérrez-Ramos was previously Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK, where he founded entrepreneurial units such as Epinova and Tempero focused in translating novel areas of science (Epigenetics, Tregs, etc) into therapeutics.

Prior to his work in the pharmaceutical industry, Dr. Gutiérrez-Ramos held senior leadership positions at several biotech companies, including Senior Vice President and Head of R&D at Avidia Inc. and Peptimmune Inc.

He began his career in the drug industry at Millennium Pharmaceuticals serving as Vice President of Inflammation Drug Discovery.

Dr. Gutiérrez-Ramos holds a Ph.D. in immunochemistry from the Autonoma University in Madrid, Spain.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST